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alongside elevations in soluble Aβ species (MOAB-2 and 
pyro-glu Aβ) and a decline in levels of the amyloid precur-
sor protein. Strong correlations were observed between 
individual Braak stages and multiple cognitive measures 
with all tau markers as well as total soluble Aβ. In contrast 
to previous reports, SDS-stable Aβ oligomers (*56) were 
not found to be reliable for all classifications and appeared 
likely to be a technical artefact. Critically, the robust pre-
dictive value of total soluble Aβ was dependent on native 
state quantification. Elevations in tau and Aβ within soluble 
fractions (Braak stage 2–3 cf. 0) were evident earlier than 
previously established in fibril-focused disease progression 
scales. Together, these data provide strong evidence that 
soluble forms of tau and Aβ co-localise early in AD and are 
closely linked to disease progression and cognitive decline.
Keywords Alzheimer’s disease · Amyloid · Tau · 
Cognitive decline · Dementia · Pathology
Introduction
The original ‘amyloid hypothesis’ postulated that aggre-
gated β-amyloid (Aβ) drives pathological mechanisms, 
results in the hyperphosphorylation of the microtubule-
associated protein tau, and causes neurodegeneration and 
cognitive decline [29]. Accordingly, much of the early work 
focused on the deposition of Aβ as senile plaques (SPs) and 
their relationship to the emergence of tau pathology. This 
work was supported by genetic mutations identified in 
familial cases of AD (fAD), and has been greatly influential 
for both experimental research and therapeutic endeavours. 
Mutations in the amyloid precursor protein (APP) and the 
presenilin (PSEN) genes clearly demonstrated that dys-
functions in APP processing are causative of dementia in 
Abstract Post-mortem investigations of human Alzhei-
mer’s disease (AD) have largely failed to provide unequiv-
ocal evidence in support of the original amyloid cascade 
hypothesis, which postulated deposition of β-amyloid (Aβ) 
aggregates to be the cause of a demented state as well as 
inductive to tau neurofibrillary tangles (NFTs). Conflict-
ing evidence suggests, however, that Aβ plaques and NFTs, 
albeit to a lesser extent, are present in a substantial subset 
of non-demented individuals. Hence, a range of soluble tau 
and Aβ species has more recently been implicated as the 
disease-relevant toxic entities. Despite the incorporation of 
soluble proteins into a revised amyloid cascade hypothesis, 
a detailed characterization of these species in the context 
of human AD onset, progression and cognitive decline has 
been lacking. Here, lateral temporal lobe samples (Brod-
mann area 21) of 46 human cases were profiled via tau and 
Aβ Western blot and native state dot blot protocols. Eleva-
tions in phospho-tau (antibodies: CP13, AT8 and PHF-1), 
pathological tau conformations (MC-1) and oligomeric tau 
(TOC1) agreed with medical diagnosis (non-AD cf. AD) 
and Braak stage classification (low, intermediate and high), 
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these cases. Yet, the contribution of specific cleavage prod-
ucts and protein aggregates to AD onset and progression as 
well as cognitive decline remains highly debated.
A prominent criticism of the amyloid hypothesis has 
been the lacking association of total plaque load with cog-
nitive status, which is in contrast to the more robust and 
graded correlation of tau pathology to neuronal loss and 
symptomatic presentation. Indeed, the highly reproducible 
regional progression of tau containing neurofibrillary tan-
gles (NFTs) and neuropil threads (NTs) provides the basis 
for neuropathological severity grading (Braak staging) 
[15]. Braak staging remains the most accepted post-mortem 
method of classifying AD progression, although amyloid 
pathology in the form of SPs and neuritic plaques must 
also be present to confer a true diagnosis of AD. Overall, 
NFTs are generally accepted as better indicators of mental 
impairment, clinical AD symptoms and neurodegeneration 
over plaque load [26, 53]. Both NFTs and NTs first emerge 
almost exclusively within the entorhinal cortex (EC) and 
hippocampal formation (transentorhinal stage, Braak stage 
1–2), this pathology alone is associated with little or no 
cognitive impairment. Only when surrounding cortical 
and subcortical structures of the limbic system are affected 
(limbic stage, Braak stage 3–4) do individuals become 
symptomatic, and definitive symptoms develop fully only 
once this neuropathology engulfs the neocortex (neocorti-
cal stage, Braak stage 5–6).
For the conclusive neuropathological diagnosis of AD, 
an evaluation of Aβ depositions via complementary neu-
rohistopathological schemes, such as the five SP-based 
Thal (Aβ) phases and CERAD (Consortium to Establish 
a Registry for Alzheimer’s Disease) staging must be made 
[12]. However, when considered independently, plaque 
deposition is less systematic cf. tau pathology and fails to 
correlate sufficiently with cognitive impairment [71]. Rela-
tive to NFTs, SP deposition follows a different spatial pro-
gression and is first observed within the neocortex [70]. 
Plaque numbers become more widespread reaching the EC 
and hippocampus long after the emergence of NFTs and 
NTs, with tau and amyloid pathologies only overlapping 
in advanced stages [73]. Such a spatial divide between the 
two pathological hallmarks makes it difficult to reconcile 
the proposed mechanistic and causative link between Aβ 
and tau, and cannot easily be incorporated into a common 
pathological scheme.
Despite this scenario, extensive research has focused 
on targeting amyloid-related pathologies for diagnostic 
purposes, e.g. based on PET amyloid imaging [78]. More 
recently, tau-based imaging markers have emerged with 
promising initial results [16]. Equally, biomarker research 
in cerebrospinal fluid (CSF) is on the hunt for multifacto-
rial biomarkers, though assays with high specificity and 
sensitivity remain elusive. For example, a recent multi-
centre study reported an age-independent occurrence rate 
of ~22 % of healthy controls (n = 1233) in which CSF Aβ 
levels were low enough to be classified as pathological, yet 
were negative for neurodegeneration and cognitively intact 
[76].
Beyond aspects related to disease diagnosis, neither Aβ 
plaques nor tau NFTs are likely the principle causative fac-
tor, as both of these forms of pathology are detected with 
considerable frequency in a subset of the non-demented 
population, referred to as non-demented high pathology 
controls (HPCs) [57]. Moreover, neurons can likely survive 
with NFT inclusions for several decades [56] and a separa-
tion of NFT formation and cognitive decline has been dem-
onstrated in animal models [68]. Recent adaptations of the 
amyloid cascade hypothesis detail critical interactions with 
tau pathology, mechanisms of early synaptic loss and high-
light central roles of soluble pre-fibril Aβ and tau species 
[55].
This shift away from insoluble pathology to poten-
tially earlier emerging soluble Aβ and tau species required 
advanced biochemical techniques to establish an under-
standing for the progression of pre-fibrillar pathology. 
Significantly, a staging of Aβ pathology in line with dis-
ease progression has been proposed based on the abun-
dance of low molecular weight Aβ species in cellular frac-
tions, resolved by SDS-PAGE, and the degree to which 
these species demonstrate biochemical modifications 
[67]. The proposed stages correlate with established neu-
ropathological grading scales, such as Braak and CERAD 
scores, to some degree, suggesting the potential for a 
stereotypical evolution of molecular pathology. How-
ever, associations with cognitive readouts and specific 
Braak stages were not included in this study. Therefore, 
a detailed evaluation of potentially pathology relevant 
soluble tau and Aβ species and their respective associa-
tion with cognitive decline and disease progression within 
human cases identified as early and late-stage AD is still 
lacking.
Here, lateral temporal lobe tissue lysates (Brodmann 
area 21) from human AD cases and non-AD controls were 
quantified for phosphorylated, conformationally altered and 
oligomeric tau species alongside amyloidogenic changes 
in APP metabolism and levels of total, monomeric, oligo-
meric and pyro-glutamate (pyro-glu) modified Aβ species. 
Markers were assessed relative to several classifications, 
i.e. based on clinical diagnosis, grouped Braak stages (Br 
0–2 cf. 3–4 cf. 5–6) as well as individual Braak stage, and 
correlated with each other as well as with cognitive decline. 
Our data demonstrate the earlier coincidence of soluble tau 
and Aβ and support the potential pathological role of both 
proteins early in the disease process of AD.
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Methods
Tissue samples
Human temporal cortex samples (n = 46, middle tempo-
ral gyrus, Brodmann area 21) and corresponding metadata 
were supplied by MRC London Neurodegenerative Dis-
eases Brain Bank, The Thomas Willis Oxford Brain Col-
lection, The Manchester Brain Bank, The Newcastle Brain 
Tissue Resource, and The South West Dementia Brain 
Bank (see Table 1). All samples were received as 500 mg 
frozen blocks and were stored at −80 °C prior to use. Cases 
were de-identified but information was provided regard-
ing age at death, post-mortem interval (PMI), cortical pH 
(where available), neuropathological assessment scores for 
Braak staging as well as CERAD neuritic plaque scores 
(where available) and cognitive scores for Mini Mental 
State Exam (MMSE) as well as global, memory and sum 
of box (SOB) scores established by the clinical dementia 
rating system (CDR). For full information regarding indi-
vidual cases and neuropathological observations see Sup-
plementary Table S1.
To serve as positive and negative immunoblot controls, 
murine forebrain samples from several transgenic strains 
were used (12-month old wild-type mice (C57/BL6) and 
12-month-old bigenic fAD mice, as previously described 
[39]). Brain lysates from 12-month-old BACE1−/− mice 
were a generous gift from Prof Michael Ashford (see [54]). 
Mice were housed and sacrificed in accordance with UK 
Home Office regulations, University European Directive 
on the Protection of Animals used for Scientific Purposes 
(2010/63/EU) and the Animal (Scientific Procedures) Act 
1986.
Immunoblot quantification of AD markers
Quantification of Aβ and tau markers was based as far 
as possible on near-native state preparations to limit the 
degree of sample manipulation required. Therefore, most 
markers were assessed by dot blots, with the exception 
of Western blots used for 6E10 and BACE1 antibodies to 
ascertain detection of single and relevant protein species. 
The oligomeric tau antibody TOC1 was also validated 
in Western blots to confirm detection of the previously 
reported oligomeric species, before samples were fully 
characterised via dot blots.
Brain lysate preparation
100 mg of frozen cortical tissue was homogenised in 
~1:10 (w/v) Igepal (Sigma, Dorset, UK) based lysis buffer 
(in mM: 20 HEPES, 150 NaCl, 0.1 EDTA, 1 % Igepal: 
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pH = 7.6). All buffers were supplemented with complete 
protease inhibitors (Roche) and PhosStop tablets (Roche). 
The use of the non-ionic, non-denaturing Igepal, which is 
chemically indistinguishable from the widely used ‘Noni-
det P-40’, ensured adequate lysis of plasma, endoplas-
mic and Golgi but not nuclear membranes, and prevented 
aggressive solubilisation of large aggregates [33]. Follow-
ing manual homogenisation, samples were spun (13,000g, 
4 °C, 20 min), supernatants separated from pellets, ali-
quoted and stored at −80 °C. For the determination of 
aggregated non-soluble protein pathology, Igepal derived 
pellets were re-suspended in excess Igepal buffer (1 ml) 
homogenised via repeated aspiration with a 1 ml pipette 
tip, briefly vortexed and spun (13,000g, 4 °C, 20 min). 
Following removal of the supernatants, the process was 
repeated. Resulting pellets were subsequently re-suspended 
in 1:1 (w/v) 70 % formic acid, incubated overnight at 4 °C 
with continuous agitation before a final spin (18,000g, 
4 °C, 20 min) to yield the collected supernatant, which was 
stored at −80 °C until use.
SDS‑PAGE electrophoresis and protein transfer
Soluble lysates were adjusted for protein concentration 
(3 µg/µl) as per bicinchoninic acid colorimetric protein 
assay (BCA, Sigma). For standard denaturing SDS-PAGE 
electrophoresis, samples were mixed with lithium dodecyl 
sulphate (LDS, Nupage, Thermo Fisher Scientific, Paisley, 
UK) and dithiothreitol (15 mM DTT, Sigma) before being 
boiled for 10 min at 70 °C. For the identification of oligo-
meric tau species, samples were treated as above, except 
without DTT or boiling prior to gel loading. Insoluble sam-
ples were first mixed with 4 volumes of neutralising buffer 
(2 M Tris + 2 M NaH2PO4) before the addition of LDS and 
DTT.
Samples (30 µg/lane for soluble and 10 µl/lane for neu-
tralised insoluble samples) were separated on 4–12 % 
Bis–Tris gels (Nupage, Thermo Fisher) under variable 
conditions dependent on protein target. For Aβ detection, 
proteins were separated for 35 min at 200 V constant volt-
age in MES buffer, transferred to 0.2 µm nitrocellulose 
membranes via IBlot (Nupage, Thermo-Fisher), and boiled 
for 3 min in 0.01 M Dulbecco’s Ca2+ and Mg2+ free phos-
phatase buffered saline (VWR International, Leicester-
shire, UK). For tau blots, electrophoresis was conducted for 
45 min at 200 V in MOPS buffer and transferred to 0.45 µm 
nitrocellulose membranes via wet transfer conditions (1 h, 
25 V constant).
Solubility and protein extractions
The specific extraction of non-fibrillar proteins from 
human tissue post-mortem was confirmed in a series of 
comparative Western blots (Supplementary Figure 1). Total 
tau, visualised by the HT-7 antibody, demonstrated the 
selective isolation of tau within well-defined protein bands 
following Igepal lysis. In contrast, subsequent treatments of 
the remaining insoluble pellet with 70 % formic acid pre-
sented a smear of HT-7 immunoreactivity. This was only 
evident in AD cases and is indicative of highly post-trans-
lationally modified and aggregated tau species as found in 
paired helical filaments and NFTs. Similarly, limited solu-
bilisation of amyloid species was observed via Igepal lysis, 
when compared to that isolated via formic acid from the 
pellet (see Supplementary Figure 1).
Native state immunoblots
To ensure the preservation of potentially heat- and confor-
mation-dependent epitopes, dot blots were conducted for a 
number of Aβ and tau pathological markers. Igepal soluble 
lysates were adjusted to 2 µg/µl with distilled H2O (concen-
tration determined with BCA assay, as above) and directly 
dotted onto 0.2 µM nitrocellulose membranes (5 µl/sam-
ples, 10 µg/dot), which were allowed to dry prior to further 
processing. In a subset of experiments, designed to deter-
mine the heat-sensitivity of specific epitopes, lysates were 
heated (70 °C for 10 min) prior to being dotted.
Blocking and antibody detection
All immunoblots were washed in 0.05 % Tween 20 (Sigma) 
containing Tris-buffered saline (TBST, in mM; 50 Trizma 
base, 150 NaCl, pH = 7.6) and blocked for 1 h at RT in 
5 % milk powder containing TBST prior to overnight incu-
bations at 4 °C with primary antibodies (see Supplementary 
Table 2) under continuous agitation. Antigen–antibody cou-
pling was visualised using appropriate secondary antibod-
ies conjugated to horseradish peroxidase (goat anti-mouse 
IgG or IgM, goat anti-rabbit IgG; 1:5000, Merk Millipore, 
Watford, UK) and enhanced chemiluminescence (1.25 mM 
Luminol, 30 µM coumaric acid, 0.015 % H2O2). All steps 
were followed by multiple washes in TBST. Processed 
blots were subsequently stained for measurements of total 
protein using Coomassie total protein stain (as described 
previously [65]). Images were captured via Vilber-Fusion-
SL camera (Vilber, Eberhardzell, Germany) at 8-bit for 
illustration and 16-bit for analysis.
To ensure specificity of the detected signal, appropriate 
secondary antibody control dot blots were conducted, in 
which the primary antibody was excluded. For all cases, no 
detectable immunoreactive signal was observed for either 
IgG or IgM secondary antibody isotype in images captured 
following exposure times of up to 3 min, which was the 
maximal exposure time required for signal detection in this 
study (data not shown).
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Immuno‑quantification
Immunoreactivity was quantified from 16-bit digitised images 
using ImageJ (Ver 1.47, NIH, USA) based on area under curve 
(AUC) measures normalised to total protein load established 
via AUCs for Coomassie processed blots. Immunoblot inten-
sity data were normalised within blots using total protein 
adjusted values and expressed relative to appropriate control 
groups (outlined below), before being pooled across blots.
Cohort stratification
To determine the relationship of investigated markers to 
the neuropsychological and pathological processes of AD, 
cases were grouped into several classifications as follows 
(see also Table 1):
1. Post-mortem confirmed clinical diagnosis, essentially 
equating to non-AD cases (=Braak (Br) 0–3) and AD 
(=Br 4–6).
2. Grouped Braak stages: low, intermediate and high 
severity of Braak pathology (Br 0–2, Br 3–4 and Br 
5–6, respectively).
3. Individual Braak score: cases listed per individual 
stages and normalised to a single Braak score (Br 2).
Statistical analysis
Statistical analysis was performed using Prism (V.6, Graph-
Pad). Data were subject to Shapiro–Wilk test for normal 
distribution prior to statistical analysis of significance 
between groups. Individual comparisons were analysed 
using either a Student’s two tailed t test or Mann–Whitney 
if determined non-parametric. Multiple group comparisons 
were established via 1-way analysis of variance (ANOVA) 
or the non-parametric Kruskal–Wallis ANOVA, if reported 
as significant, selected pair comparisons were conducted 
via post hoc Bonferroni or Dunn’s tests, respectively. Anal-
ysis of covariance (ANCOVA) was employed to control 
for PMI and tissue pH (Minitab 17). Correlation analysis 
was conducted using Spearman’s ranks correlation, which 
does not assume normality of data sets. Having established 
either positive or inverse correlation of markers in relation 
to Braak stages, individual Braak stages were probed for 
significant deviation from Braak 0 via a one-tailed t test. 
For all tests, p < 0.05 was taken as significant with subse-
quent levels of statistical reliability reported for p < 0.01, 
p < 0.001 and p < 0.0001.
Results
Demographic data and cognitive scores
Prior to the investigation of pathological markers, bio-
graphical data and post-mortem interval were investigated 
for potentially confounding factors with regards to patho-
logical measures. Independent of analytical classification 
no significant difference in age, PMI or frontal cortical 
pH was determined between groups (Table 1). With the 
exception of Braak stage 0 (100 % male) and Braak stage 
5 (83.3 % male), the cohort was reasonably balanced for 
gender. Scores of cognition as established by the MMSE 
(Fig. 1a, r = −0.67, p < 0.0001, n = 42), CDR global 
(Fig. 1b, r = 0.69, p < 0.0001, n = 43), CDR memory 
(Fig. 1b, r = 0.69, p < 0.01, n = 43) and CDR sum of 
box scores (data not shown, r = 0.55, p < 0.001, n = 33) 
closely followed Braak stage progression, but not age (data 
not shown).
Quantification of tau pathology
Initially, phospho-tau pathology was investigated via immu-
noblots of soluble lysate, established to selectively extract 
Fig. 1  Cognitive performance during disease progression. Assess-
ment scores from ‘Mini Mental State Exam’ (MMSE, a) as well as 
global and memory scores from the ‘Clinical Dementia Rating’ 
(CDR, b) are correlated with disease progression based on Braak 
stage. Significances (p) and Spearman’s correlation index (r) are 
provided within each graph. Data are expressed as mean ± SEM, 
****p < 0.0001
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non-fibrillar protein species (see Supplementary Figure 1). 
The phospho-specific antibody AT8 recognises tau phos-
phorylated at serine 199, serine 202 and threonine205 
residues (p-ser199/ser202/thr205) [9, 27] and is commonly 
employed by pathologist for post-mortem confirmation of 
AD diagnosis and for the staging of tau pathology accord-
ing to Braak stage. Under dot blot conditions, which negate 
alterations in the electrophoretic mobility of tau between 
samples, due to different degrees of protein phosphoryla-
tion [17] and allows for quantification of total tau species 
phosphorylated at each investigated epitope, AT8 immuno-
reactivity was strongly enhanced in AD diagnosed cases, 
reporting a ~14-fold increase compared to non-AD samples 
(Fig. 2a i + ii, p < 0.001). A graded increase in AT8 phos-
pho-tau was also observed across grouped Braak stages 
(Fig. 2aii, low: Br 0–2, intermediate: Br 3–4, high: Br 5–6, 
p < 0.0001). Post hoc analysis demonstrated significant 
elevations between low and intermediate (p < 0.01) and 
low and high classifications (p < 0.0001), yet not between 
intermediate and high (p > 0.05). In accordance with the 
use of AT8 for the histopathological classification of tau 
pathology, dot blot quantification of soluble AT8 phospho-
tau demonstrated a strong correlation with Braak staging 
(Fig. 2aiii, r = 0.81, p < 0.0001), initial elevations of AT8 
Fig. 2  Phospho-tau pathology. Dot blots for a AT8, b PHF-1, c 
CP13 phospho-tau immunoreactivity. Cases within example dot blots 
are labelled for diagnosis [non-AD control cases (‘C’) and AD] and 
Braak stage (Br). Analyses stratified for ii) diagnosis, iii) severity 
(Low: Br 0–2, Intermediate (Inter): Br 3–4 and High: Br 5–6), and 
(iv) correlation with individual Braak stages are shown. Statistical 
outcomes are depicted as **p < 0.01, ***p < 0.001, ****p < 0.0001 
and Spearman’s correlation (r). The earliest Braak stage at which 
immunoreactivity was significantly elevated from Braak 0 is also 
indicated ($)
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phosphorylation being reported as significant from Braak 
0 at Braak 4 (p < 0.05), which is in line with Braak stage 
progression for Brodmann area 21, reportedly affected at 
Braak stage 4 [2].
Tau phosphorylation was further investigated using two 
other commonly employed phospho-tau antibodies, PHF-1 
(Fig. 2b, p-ser396/ser404) and CP13 (Fig. 2c, p-ser202). As 
for AT8, PHF-1 and CP13 reactivity was increased in AD 
compared to non-AD cases (Fig. 2bii + cii, 9- and 13-fold 
increase for PHF-1 and CP13, respectively, p < 0.0001 for 
both). Both PHF-1 and CP13 levels also increased with 
pathology severity (Fig. 2biii + ciii, p < 0.0001), report-
ing elevations within intermediate and high Braak stages 
compared to low pathology cases. Also, strong correla-
tions with individual Braak stages were observed with 
PHF-1 and CP13 (Fig. 2biv + civ, r = 0.80, p < 0.0001 for 
PHF-1 and r = 0.77, p < 0.0001 for CP13). For the three 
phospho-epitopes, CP13 changes were detected earliest 
(Br 0 cf. Br 2: p < 0.05) and PHF-1 latest (Br 0 cf. Br 5, 
p < 0.05). Phospho-tau dot blots were validated for speci-
ficity by means of correlation of immunoreactivity with 
traditional Western blots in a subset of cases for PHF-1 
(r = 0.79, p < 0.0001, n = 18, data not shown). A sig-
nificant effect of Braak stage (F(5,80) = 10.47, p < 0.0001) 
and epitope (F(2,80) = 8.61, p < 0.001) and an interaction 
(F(10,40) = 2.43, p < 0.05) was reported when comparing 
the phospho-epitope specific antibodies, likely due to the 
variable magnitude of hyperphosphorylation and differen-
tial antibody affinities apparent between Braak stages 2–4. 
Nevertheless, further analysis demonstrated a robust effect 
of subject matching, indicating those cases with high AT8 
staining also demonstrated high levels of CP13 and PHF-1 
staining. This is perhaps unsurprising given the similarity 
of dot blot immunostaining between epitopes (see example 
blots in Fig. 2).
Conformational and oligomeric tau
Although hyperphosphorylation is the most extensively 
studied aspect of tau pathology, several additional pro-
tein modifications offer further key parameters in dis-
ease pathology. Conformational changes in the natively 
unfolded structure of the tau protein, leading to an interac-
tion of the N-terminal domain with the microtubule binding 
domain (MTBD), may be closely modulated by phospho-
rylation status [81].
Alz-50 was the first antibody derived from paired helical 
filaments to recognise such a conformational change [37]. 
Here, its immunoreactivity was unaltered between Non-AD 
and AD cases (‘diagnosis’) and did not increase when con-
sidered across grouped Braak stages (Fig. 3ai–iii, p < 0.05). 
Despite a failure to detect differences between diagno-
sis and severity groups, a modest correlation between 
Alz-50 and Braak stage was observed (Fig. 3aiv, r = 0.32, 
p < 0.05), likely driven by the increase between individual 
stages (note Br 2 elevation compared to Br 0, p < 0.01). 
The use of the Alz-50 antibody may be confounded by its 
cross-reactivity with an uncharacterised developmentally 
regulated protein (Foetal Alz-50-reactive 1 clone protein, 
FAC1) [14], thus tau conformational changes were further 
probed with the related MC-1 antibody, which does not 
cross-react with FAC1 [37]. MC-1 immunoreactivity was 
distinct from that of Alz-50, detecting a highly selective 
signal in AD cf. Non-AD cases (Fig. 3bi + ii, p < 0.0001) 
and was enhanced in accordance with grouped Braak 
stages (Fig. 3biii, p < 0.0001), principally derived from 
the level of reactivity within the high category (low cf. 
high: p < 0.001; intermediate cf. high: p < 0.01). A strong 
correlation with MC-1 positive conformational tau and 
Braak stage was apparent (Fig. 3b, r = 0.60, p < 0.0001), 
and determined as elevated from ≥Br 4 relative to Br 0 
(p < 0.05).
In addition to the emergence of conformational tau 
pathology, formation of oligomeric tau species has been 
proposed to correlate with behavioural deficits in animal 
models [7] and was also previously reported to be elevated 
in human AD cases [40, 64, 79]. TOC1 binds to a confor-
mation-dependent epitope preferentially exposed upon 
oligomerisation (aa209–224) [79], and here recognised a 
single band when tested in Western blot applications under 
non-denaturing conditions (no DTT or boiling, ~180 kDa; 
Fig. 3c i, for full blot see Supplementary Figure 2). This 
band was previously established via SELDI-TOF MS as a 
tau dimer [63]. TOC1 immunoreactivity was characterised 
in all cases via native state dot blots (Fig. 3cii) and robustly 
increased for AD compared to non-AD cases (Fig. 3ciii, 
p < 0.0001), significantly tracked across grouped Braak 
stages (Fig. 3civ, p < 0.0001) and correlated with individual 
Braak stage (Fig. 3cv, r = 0.59, p < 0.0001). Relative to 
Braak stage 0 a significant elevation in reactivity emerged 
at Braak stage 5 (p < 0.05), although in a subset of cases 
a strong signal prior to this was apparent (Br 4 cf. Br 0, 
p = 0.07).
Correlations of tau biomarkers
Correlative analysis of each pathological tau marker within 
our soluble preparation demonstrates a variable degree of 
agreement between all tau markers, with the exception of 
Alz-50 (Table 2). Interestingly, prominent markers for con-
formational and oligomeric tau yielded high correlations 
with differential phosphorylation epitopes (MC-1 with 
PHF-1 and TOC1 with CP13). No correlation with PMI, 
cortical pH or age was observed with any of the mark-
ers tested; this was further confirmed by ANCOVAs (all 
p’s > 0.05).
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Fig. 3  Conformational and oligomeric tau pathology. a Alz-50 and b 
MC-1 conformational tau and c oligomeric tau (tau-oligomeric-com-
plex 1; TOC1) dot blots. The inset (C) illustrates an example Western 
blot for TOC1 run under non-reducing, non-denaturing conditions, 
labels show diagnosis status (C = non-AD and AD). In A–C, quantifi-
cations of immunoreactivity is categorised according to diagnosis (ii), 
severity (iii, low: Br 0–2, intermediate (Inter): Br 3–4 and High: Br 
5–6) and correlation with Braak stage (iv). Significances are indicated 
as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 and 
Spearman’s correlation (r). The lowest Braak stage at which immu-
noreactivity was significantly elevated from Braak 0 is indicated by $
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APP processing and pathology
Amyloidogenic processing
Immunoblotting with the commonly used antibody 6E10, 
which is raised towards the human Aβ1-16 sequence, pro-
duced multiple bands in Western blots corresponding 
to various APP metabolites as well as full-length APP 
(fAPP). The major 6E10 immunoreactive band migrated 
between 80 and 120 kDa and was consistently observed 
in lysates from human samples and a hAPP overex-
pressing mouse (Fig. 4a i). This primary band equates 
to various post-translational modified species of fAPP 
and was evidently reduced between AD and non-AD 
cases (Fig. 4a ii, p < 0.05) but failed to reach signifi-
cance across grouped Braak stages (Fig. 4a iii, p = 0.09). 
Levels of fAPP did, however, correlate (negatively) with 
the progression of Braak stage (Fig. 4a iv, r = −0.39, 
p < 0.01); post hoc analysis indicated this to be due to 
a significant reduction in the levels of fAPP as early as 
Braak stage 2 (p < 0.05 for Br 2 vs Br 0). Similar trends 
for the reduced expression of fAPP were also observed 
following the use of an N-terminal APP directed antibody 
(see Supplementary Figure 3).
The reduction of fAPP with diagnosis and disease 
severity may suggest a facilitation of APP cleavage via 
amyloidogenic secretases in AD cases. Several groups 
have previously reported a disease-dependent increase 
in BACE1 and thus a promotion of Aβ production path-
ways [24, 34]. However, despite the decrease of fAPP, 
BACE1 expression levels were unaltered in any of the 
analytical stratifications (Fig. 4b; p > 0.05 for all).
Aβ species
The detection of Aβ species, from monomers to oligomers, 
is problematic due to a number of confounding factors such 
as the cross-reactivity of many Aβ-directed antibodies with 
similar-sized non-Aβ APP metabolites and the potential 
for experimental parameters to modify Aβ self-oligomer-
ization [80]. Probing standard Westerns blots with 6E10 
detected immunoreactive bands migrating at 4 kDa equat-
ing to monomeric Aβ and 12 kDa band potentially equat-
ing to trimeric Aβ or C-terminal fragments of APP. The 
12 kDa band was not quantified here, but also was detected 
in lysates from hAPP overexpressing mice, yet absent in 
wild-type mouse lysates (see example in Fig. 5a i). Initial 
quantification of monomeric Aβ (all cases), demonstrated a 
~6-fold increase in monomeric Aβ levels in AD relative to 
non-AD cases (Fig. 5a ii, p < 0.0001) and an overall effect 
of grouped Braak stages (Fig. 5a iii, p < 0.001). Post hoc 
analysis demonstrated that significance was principally 
driven by the elevation at late stages (Br ≤ 2 cf. Br ≥ 5, 
p < 0.001 and Br 3–4 cf. Br ≥ 5, p < 0.001). Interestingly, 
a strong correlation with Braak stage was also established 
(r = 0.57, p < 0.0001) but the increased Aβ immunoreac-
tivity did not reach significance from Braak stage 0 until 
stage 5 (p < 0.01).
Quantification of monomeric Aβ based on all cases 
is questionable as it relies on the inclusion of data from 
samples lacking a discernible band (i.e. signal value near 
background). The absence of detectable soluble Aβ in 
mildly dissociated tissues (manual homogenisation as 
opposed to sonification) using Western blots has previ-
ously been established [38], therefore, quantification in 
Table 2  Correlations of tau 
pathology markers Markers
Phosphorylation Conformational
AT8 PHF-1 CP13 Alz-50 MC-1
Oligomeric TOC1
****; 
r = 0.67
****; 
r = 0.68
****; 
r = 0.74
N.S.
***; 
r = 0.52
Conformation
MC-1
**; 
r = 0.52
****; 
r = 0.57
*; r = 0.48 N.S.
Alz-50 N.S. **; r = 0.38 N.S.
Phosphorylation
CP13
****; 
r = 0.88
****;
r = 0.81
PHF-1
****; 
r = 0.9
Results are organised according to tau species subtypes and antibodies used
Significances (p) and outcome from Spearman’s correlation (r) between each marker and statis-
tical reliability are shown and visualised by means of graded shading. * p < 0.05, ** p < 0.001, 
*** p < 0.001 and **** p < 0.0001. N.S. not significant
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this fashion cannot be considered technically robust. Oth-
ers have employed direct measurements using densitometry 
(for example [49, 67]), but failure to adjust for inter-blot 
differences in background and signal intensity may intro-
duce additional noise into the data. More appropriate anal-
ysis arises from monomeric Aβ levels quantified only for 
those samples in which a band can be clearly detected (16 
out of 19 AD samples, 14 out 27 non-AD samples). With 
this approach (termed monomeric Aβ positive, Fig. 5c i), 
monomeric Aβ was confirmed to be elevated for AD diag-
nosed cases relative to Non-AD controls (p < 0.01) and 
demonstrated a significant effect of grouped Braak staging 
(Fig. 5c ii p < 0.001), yet post hoc analysis demonstrated 
only a significant elevation between Braak stage 3–4 and 
5–6 (p < 0.001) but not Braak stages 0–2 (p > 0.05). Nor-
malisation of the data set to Braak stage 2 was not possible 
due to the inconsistent detection of monomeric Aβ within 
cases of low-stage pathology. Other higher molecular Aβ 
aggregates have attracted attention in the past, for exam-
ple, the frequently reported dodecameric Aβ*56 [48, 49]. 
A corresponding band was detected here following longer 
exposure times, which revealed several additional bands on 
Fig. 4  Amyloid precursor protein cleavage. Exemplary Western blots 
for a full-length APP detected via 6E10 immunoreactivity, and b 
β-secretase (BACE1) are illustrated. Braak stage (Br) and diagnosis 
(non-AD (C) cf. AD) are stated above each sample. Positive (+ve) 
control: human APP overexpressing mouse and negative (−ve) con-
trol (in a: wild-type C57/BL6 mouse and in b: BACE1−/− mouse) are 
included. Total protein normalised immunoblot signals were analysed 
according to diagnosis (ii), severity (iii, low: Br 0–2, intermediate 
(Inter): Br 3–4 and high: Br 5–6) and Braak stage correlation (iv). 
Statistical results are presented as *p < 0.05, **p < 0.01 and Spear-
man’s correlation (r) are stated in the graphs. $ indicates the lowest 
Braak stage at which immunoreactivity differed significantly from 
Braak 0
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Western blots probed with 6E10 (Fig. 6a). In a subset of 
cases (n = 16), we attempted to quantify and validate the 
*56 band. Although no significant difference between diag-
nosis or severity groups could be established (Fig. 6b i–ii), 
an apparent decline in *56 levels with Braak stage was 
observed (Fig. 6b iii) in agreement with previous reports 
[49]. However, Western blot protocols pose several techni-
cal issues for the identification of Aβ oligomers due to spe-
cies modifications induced by reducing agents and heating 
of samples. Therefore, samples were also run under quasi 
non-denaturing conditions as conducted for TOC1. Under 
these near-native state conditions (Fig. 6a), the detection 
of *56 was greatly diminished and no consistent alteration 
was observed in any analytical stratification for any group 
(Fig. 6a + c), indicative that potential artefacts induced by 
standard SDS-PAGE methods had likely modified native 
Aβ species.
As an alternative means of quantifying soluble Aβ load, 
non-denaturing dot blots were stained with the Aβ-selective 
antibody MOAB-2, which does not cross-react with APP or 
other metabolites [77]. Here, Aβ was consistently detected 
in all AD cases, with levels robustly elevated in diagnosed 
relative to Non-AD samples (Fig. 7a ii, p < 0.0001); the 
signal increased progressively across grouped Braak stages 
Fig. 5  Monomeric β-amyloid (Aβ). Immunoblot for a monomeric 
Aβ (6E10 antibody). Diagnosis (Non-AD (C) cf. AD) and Braak 
stage is stated for each case. Positive (+ve) control: human APP 
overexpressing mouse and negative (−ve) control (wild-type mouse) 
samples are also shown. Size comparison was established via a 
Coomassie stained low molecular weight protein ladder (insert). 
Quantification was conducted either for all cases (b) or only for sam-
ples where a band was evident (c), the percentage (%) of cases in 
which monomeric Aβ was detected is stated below the graph. Total 
protein adjusted immunosignal stratified to i) diagnosis ii) severity 
(Low: Br 0–2, Intermediate (Inter): Br 3–4 and High: Br 5–6) and iii) 
correlation with individual Braak stage. Significances are illustrated 
as ***p < 0.001, ****p < 0.0001, Spearman’s correlation is also 
stated. $: indicates the earliest Braak stage at which immunoreactivity 
was higher than that observed at Braak stage 0
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(Fig. 7a iii, p < 0.0001). Further statistical comparison 
revealed strongest elevations in Braak 5–6 cases compared 
to Braak 0–2 (p < 0.001) and Braak 3–4 (p < 0.05). The 
progressive increase in soluble Aβ load was further con-
firmed by the positive near-linear correlation of MOAB-2 
reactive species with Braak stage (Fig. 7a iii, r = 0.71, 
Fig. 6  Heat-dependent detection of Aβ oligomers. a Side by side 
comparison of 6E10 immunoreactivty following boiling and non-
boiling of samples prior to SDS-PAGE separation. Monomeric, 
trimeric and *56 Aβ bands are indicated alongside individual diag-
nosis (C non-AD control and AD cases) and Braak stage (Br) clas-
sifications. Quantification of *56 oligomeric Aβ levels according to i) 
diagnosis, ii) severity (Low: Br 0–2, intermediate (Inter): Br 3–4 and 
High: Br 5–6) and iii) correlation to individual Braak stage for boiled 
(b) and non-boiled (c) samples
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p = 0.0001). MOAB-2 levels were initially detected 
as enhanced at Braak stage 3 relative to Braak stage 0 
(p < 0.05).
Next, cases were further probed for post-translational 
modification of Aβ species with pyro-glu [21]. In Western 
blots, a single immunoreactive band was identified migrat-
ing ~12 kDa, which in a subset of samples approached 
significant elevations based on diagnosis and when sam-
ples grouped in low, intermediate and high Braak stages 
(p = 0.07 and p = 0.08, respectively), but did correlate 
with individual Braak stages (r = 0.32, p < 0.05; data not 
shown). When all cases were characterised in non-denatur-
ing immuno-dot blot conditions, pyro-glu Aβ immunore-
activity was enhanced based on diagnosis criteria (Fig. 7b 
i, p < 0.05), increased in line with grouped Braak stages 
(Fig. 7b ii, p < 0.05) and correlated with individual Braak 
stage (Fig. 7b iii, r = 0.32, p < 0.05). Post hoc analysis 
indicated that significance was largely driven by late-stage 
pathological changes (Br 5–6 cf. Br ≤ 2, p < 0.05), yet 
no individual Braak stage was significantly elevated from 
Br 0 cases. As can be seen in scatter plots in Fig. 7b, sig-
nificance was primarily driven by two highly reactive AD 
cases, however, further investigation (Grubb’s outlier test) 
did not report these as significant (p > 0.05).
To further characterise the impact of heating on Aβ and 
their detection, boiled and unboiled lysates were transferred 
onto nitrocellulose membranes. Under boiling conditions, the 
diagnosis-specific increase of Aβ as detected by MOAB-2 
was abolished and even appeared reduced relative to Non-
AD cases (Fig. 8a i–ii, p = 0.09). The heat-sensitive nature 
of MOAB-2 mediated Aβ detection was further confirmed by 
a two-way ANOVA, comparing across grouped Braak stages 
(Fig. 8a iii, Braak stages: F(2,26) = 0.83, p > 0.05, boiling: 
F(1,26) = 5.9, p < 0.01 and interaction: F(2,1) = 3.8, p < 0.05). 
In comparison, the detection of phospho-Tau was unaffected 
by boiling (see Supplementary Figure 4).
Correlation between Aβ‑related biomarkers
The various Aβ-related markers failed to demonstrate a sim-
ilar interrelated pattern as observed for tau (Table 3). Never-
theless, fAPP measurements inversely correlated with quan-
tified levels of MOAB-2 reactive Aβ, which itself correlated 
with monomeric and pyro-glu Aβ, as one would expect for 
Fig. 7  Soluble Aβ detection. Example immunoblots for a i) 
MOAB-2 and b i) pyro-glu reactive Aβ; each case is labelled with 
corresponding diagnosis [Non-AD (C) cf. AD] and Braak stage. 
Quantified signals normalised to total protein are shown stratified to 
ii) diagnosis iii), severity (Low: Br 0–2, Intermediate (Inter): Br 3–4 
and High: Br 5–6) and iv) correlation with Braak stage. *p < 0.05, 
***p < 0.001, ****p < 0.0001 and Spearman’s correlation r is stated 
in iv. $ denotes lowest Braak stage at which immunoreactivity dif-
fered from Braak 0
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a signal derived from a metabolite of APP. No correlation or 
effect of cortical pH or PMI as covariates was observed for 
any of the Aβ markers examined here (p > 0.05).
Tau and Aβ: mutual correlations
The correlations identified for tau and amyloid markers 
imply a relationship of components within the categories of 
tau and amyloid species. Determining correlations between 
these pathologies is of critical importance, particularly in 
light of the early stage emergence of both soluble tau and 
amyloid (Table 4). Accordingly, soluble MOAB-2 reac-
tive Aβ was the only Aβ-related marker to correlate with 
all markers of tau pathology, and best matched with phos-
pho-tau markers PHF-1 and AT8 (r > 0.63, p < 0.0001 for 
Fig. 8  Heat sensitivity of 
soluble Aβ (MOAB-2 epitope). 
(i) Dot blots of either boiled 
or non-boiled samples probed 
with MOAB-2 for oligomeric 
Aβ. Diagnosis [non-AD (C) 
and AD] and Braak stage (Br) 
are shown for each sample. 
Matched samples for boiled 
vs non-boiled conditions were 
analysed according to diagnosis 
(ii) and severity (low: Br 0–2, 
intermediate (Inter): Br 3–4 and 
high: Br 5–6) (iii). Statistical 
outcome of a two-way ANOVA 
is reported in the correspond-
ing graph. *p < 0.05 and 
***p < 0.001
Table 3  Correlations between amyloid pathology markers
Markers
APP Secretase Aβ
fAPP (6E10) BACE1 Pyro-glu Mono (6E10)
Aβ
Soluble
(MOAB) *; r=-0.34 N.S. *; r=0.31 *; r=0.34
Mono
(6E10) N.S. N.S. N.S.
Pyro-glu N.S. N.S.
Secretase BACE1 N.S.
Components of the amyloidogenic cascade listed are full-length APP (fAPP) as detected via 6E10 APP antibody, β-secretase (BACE1), mono-
meric Aβ (mono Aβ) as detected by 6E10, soluble Aβ as detected by MOAB-2 and pyro-glu Aβ
Significances (p) and Spearman’s correlation (r) between each component are provided. * p < 0.05. N.S. not significant
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both). These observations were further strengthened by the 
reciprocal, inverse correlations of oligomeric (TOC1), con-
formational (MC-1) and phospho-tau (CP13 and AT8) with 
total fAPP. In contrast to soluble MOAB-2-reactive Aβ, 
monomeric Aβ and pyro-glu Aβ correlated more selectively 
with phospho-tau and oligomeric tau epitopes.
Pathological correlates of Braak staging and cognition
The overall robust correlations of both tau and Aβ markers 
with Braak stages are summarised in Table 5 and listed along-
side associations obtained with cognitive measures. Outcomes 
were in close agreement with each other, reporting strong cor-
relations with all phospho-tau markers but also with confor-
mational tau (MC-1) and oligomeric tau (TOC1). Critically, 
for amyloidogenic processing soluble MOAB-2 reactive Aβ 
consistently reported a high level of correlation with cognitive 
decline, approximately matching the correlative strength of tau 
markers. Monomeric Aβ also strongly correlated with cogni-
tive decline, however, this must be viewed with caution due to 
the lack of reliable detection in some AD cases.
Discussion
Taupathology
Quantification of soluble, abnormally phosphorylated tau 
detected in brain lysates was highly predictive of the clini-
cal diagnosis and rose with the severity of neuropathologi-
cal classifications, regardless of the phospho-epitope. In 
agreement with the stereotypical progression of NFTs over 
the course of AD, phosphorylation at the AT8 epitope was 
first significantly elevated at Braak stage 4 [2, 15]. Classi-
cally based on the detection of NT and NFTs via argyro-
philic stains, modern Braak staging utilises AT8 and thus 
includes the additional detection of pre-tangle tau. The 
accumulation of soluble, phosphorylated tau is evident 
within the temporal cortex and precedes mature tau lesions 
in many low Braak stage (I–III) cases [2]. Here, tau species 
detected in our soluble fraction most likely reflect changes 
within pre-tangle neurons rather than NF and NFTs, and 
already appeared at Braak stage 2 (CP13). All three phos-
pho-tau antibodies strongly correlated with Braak stages, 
in close agreement with previous reports [84]. This was 
nevertheless surprising given the well-documented post-
mortem reduction in phosphorylation [23], largely due to 
the energy-independent activity of phosphatases. Although 
samples used in the current study had longer PMIs com-
pared to those from some previous publications, no impact 
of PMI as covariate or correlation of any marker with PMI 
was observed. Moreover, no evidence for protein degrada-
tion was detected in either blotting techniques. Ultimately, 
the long PMIs may have resulted in an under-estimation of 
pathological tau phosphorylation but strong correlations 
of phospho-tau markers with other pathological markers 
as well as cognition provide evidence for reliable disease 
tracking.
The rise of tau phosphorylation at Braak stage 2 was 
mirrored by the conformation-specific antibody Alz-50, 
although as previously discussed non-specific FAC1 bind-
ing may be a confounding factor here [14]. The improved 
MC-1 antibody [37, 81] demonstrated a superior signal 
associated with diagnosis, Braak staging and cognitive 
decline. However, MC-1 reactive tau was not elevated sig-
nificantly until Braak stage 4, at which point both CP13 
and AT8 phosphorylation markers were also raised. Tau’s 
ability to adopt folded MC-1-reactive conformation may 
be increased in situ following phosphorylation at multiple 
sites as has been observed in vitro [36]. Hence, changes in 
phosphorylation may indeed be required before conforma-
tional changes can occur [51].
Previous studies have shown a robust increase in TOC1 
reactivity in AD compared to control samples [40, 63], but 
Table 4  Correlations between tau and amyloid markers
Markers
APP Secretase Aβ
fAPP
(6E10) BACE1 Pyro-glu
Mono 
(6E10)
Soluble 
(MOAB)
Oligomeric TOC1 *; r=-0.33 N.S. N.S. *; r=0.29 ***; r=0.52
Conformaon
MC-1 **; r=-0.39 N.S. N.S. N.S. **; r=0.38
Alz-50 N.S. N.S. N.S. N.S. *; r=0.34
Phosphorylaon
CP13 *; r=-0.32 N.S. N.S. *; r=0.32 ****; r=0.63
PHF-1 N.S. N.S. *; r=0.34 **; r=0.41 ****; r=0.64
AT8 **; r=-0.46 N.S. *; r=0.37 N.S. **; r=0.45
Data are organised according to the components of the amyloidogenic cascade (horizontal axis) or tau pathology (vertical axis). Spearman’s cor-
relation (r) between each component and statistical strength (p) is shown. Intensity of shading visualises strength of correlation
* p < 0.05, ** p < 0.001, *** p < 0.001 and ****  p < 0.0001. N.S. not significant
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have not assessed the association of TOC1 with disease 
progression and cognitive impairment scores. Thus, an 
important conclusion from our data is that oligomeric tau 
appears to be a strong predictor of cognitive scores, clinical 
diagnosis and neuropathological severity. Recent experi-
mental studies have indeed linked low-weight oligomeric 
tau rather than fibrillary species to e.g. increased neuronal 
toxicity, impaired axonal transport, inhibition of synap-
tic plasticity, synaptic loss, mitochondrial impairment and 
memory deficits [22, 46, 47, 63, 64]. Overall, our data lend 
direct support to the patho-physiological relevance of non-
filamentous, oligomeric tau. Nevertheless, strong correla-
tions with cognitive decline were also observed for confor-
mational and phospho-tau as previously reported in humans 
[25, 30] and animal models [43, 44, 83]. Our data expand 
on the suggested disruptive role of monomeric phospho-
tau [41], and suggest oligomerization caused by patho-
logical modification of monomeric tau to play a key role. 
Factors causing the formation of oligomeric tau species 
remain largely undefined, but native tau does not appear 
to readily self-aggregate under near-physiological condi-
tions [20, 42]. Not surprisingly, several post-translational 
modifications facilitate tau aggregation, and our current 
work implies facilitation of oligomerisation via multiple 
phospho-epitopes, consistent with the extensive co-local-
ization between TOC1 and phospho-ser422 tau, an early 
pre-tangle phospho-epitope [28], in the EC and cholinergic 
basal forebrain [63]. Conversely, tau oligomers do not read-
ily co-localise with markers of more mature fibrillary tau 
species [63, 79]. Taken together, the coincident appearance 
Table 5  Correlation of tau and amyloid markers with Braak stage and cognitive scores
Significances (p) and Spearman’s r correlations are given for each marker (for details, see previous Tables) with Braak stage as well as with cog-
nitive scores [established via the Mini mental state exam (MMSE) and Global, Memory and Sum of Box (SOB) variants of the clinical dementia 
rating (CDR)]. The strength of correlation is indicated by the intensity of shading. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001, 
N.S. not significant
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of phospho-epitopes and oligomerization is supportive of 
the suggestion that abnormal phosphorylation may facili-
tate tau oligomerization [35] thus generating pathologi-
cal tau entities early in the disease process. Nevertheless, 
future studies are required to better define which phospho-
epitopes are directly involved in this process in situ.
With respect to measures of cognitive ability, all markers 
except Alz-50 provided robust associations. As we focused 
here on tau species that are soluble in mild detergent, non-
denaturing conditions, our findings strongly suggest that 
soluble tau is sufficient and relevant for cognitive impair-
ment, and adds support to the proposition that soluble path-
ological species are more relevant to disease progression as 
opposed to the NFT and plaque inclusions [11]. Correla-
tions obtained here were clearly stronger than previously 
reported for NT and NFTs in AD and MCI cases [59], 
despite the limited number of cases and varying origin.
APP processing and soluble Aβ species
Early stage alterations in Aβ markers were twofold: a 
diagnosis-specific, progressive decline in fAPP and a cor-
responding increase in MOAB-2 reactive Aβ species. The 
progressive decline of fAPP is in contrast to many other 
studies, which found either no change [8, 60] or an increase 
[3, 82]. There are several possible explanations for this 
inconsistency, but perhaps the most pertinent is the com-
position of sample groups. None of the previous investi-
gations had quantified APP levels according to individual 
Braak staging, and here the greatest loss of APP was seen 
between Braak stage 0 and 2, two stages often pooled into 
a non-AD control groups. Thus, the early loss of total APP 
levels may have been overlooked.
The observed reduction in APP may be a consequence 
of transcriptional downregulation [75], however, the strong 
negative correlation between total APP and soluble Aβ 
species suggests increased amyloidogenic APP cleavage. 
Whilst no change in the expression levels of BACE1 was 
observed (in contrast to the investigations of others [24, 
34]), we cannot rule out the possibility of increased BACE1 
activity in AD [1, 24, 72].
Regarding Aβ species, monomeric, pyro-glu modified 
and total soluble levels were elevated according to diag-
nosis and Braak stage severity. These forms of Aβ also 
robustly correlated with individual Braak stages and both 
monomeric and soluble levels of Aβ further correlated, 
albeit to varying degrees, with measurements of cognition. 
Our data also suggest that detection of monomeric Aβ via 
Western blots is not always possible, particularly in non-
AD cases, but also in a number of AD cases. The apparently 
low levels of soluble monomeric Aβ agree with recent find-
ings which indicate a potential over-estimation of respec-
tive Aβ species following aggressive tissue homogenisation 
via sonification [38]. Genuine soluble, monomeric Aβ spe-
cies may in some cases be below the detection limit of con-
ventional Western blotting, even in cases with Braak stage 
5 pathology [38]. Detection of Aβ may be further compli-
cated, as even common antibodies such as 6E10 and 4G8 
may only bind sub-species of Aβ, dependent on conforma-
tion [33]. Regardless of the analytical parameters, mono-
meric Aβ was elevated in agreement with both diagnosis 
and Braak stage, closely matching data from others [67]. 
Yet, a significant increase occurred only in advanced path-
ological cases and did not follow a progressive scale, in 
agreement with previous observations [49].
Oligomeric Aβ
Our data strongly suggest that chemical and physical 
parameters of standard Western Blot techniques are not 
suitable for the reliable detection of native Aβ species. 
Although numerous potential SDS-stable Aβ oligomers 
were visible following the overexposure of 6E10 blots, it 
is far from clear if any of these entities are native to the 
brain and/or disease relevant. Specifically, this relates to 
the oligomeric species known as *56, a dodecamer of Aβ, 
which has been identified in several animal models [18] 
including our own [65], and found to decrease as a func-
tion of disease [49]. It has been suggested to be an indica-
tor of a prodromal time window, triggering degenerative 
cascades before sequestration into increasingly insolu-
ble plaque deposits. Here, such an inverse relationship 
between disease severity and this oligomeric Aβ species 
also seemed apparent, declining from early Braak stage 
cases to high pathology cases. However, the utility of such 
SDS-stable oligomeric species must be questioned when 
considering that the presence of SDS, even at low con-
centrations (0.2 %) can greatly enhanced the abundance 
of dimeric [80] trimeric [10] and higher, multimeric Aβ 
species [5, 31, 32, 66]. Furthermore, and in line with the 
impact of heat and reducing agents such DTT to modulate 
amyloidogenic β-sheet aggregation [13, 45, 69], we dem-
onstrate that the relative abundance of *56 was strongly 
reduced and any correlation with disease progression lost 
in the absence of such treatments. This suggests that some 
of the previous data may be due to technical artefacts. The 
observation of highest levels of *56 in Braak stage 0 cases 
is also somewhat at odds with the hypothesis of *56 being 
pathologically causative, as one would anticipate lowest 
levels in healthy adults and thus at least an initial eleva-
tion between what is considered a pathology-free status 
(Br 0) and those cases assumed to be at risk of developing 
AD (Br 2 and 3).
Contrary to SDS-PAGE resolved oligomers and mono-
mers, dot blot detection of soluble unmodified oligomeric 
Aβ allowed consistent detection and demonstrated a robust 
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disease-specific increase and a progressive correlation with 
Braak stages and cognitive decline. Critically, this rela-
tionship was completely abolished following heating and 
induced a similar inverse relationship with disease progres-
sion, as observed for *56. Together, our data strongly sug-
gest that artificial modification of Aβ species has hampered 
many previous studies, via promotion of soluble Aβ species 
into oligomeric configurations which may mask epitopes or 
destroy binding sites. The heat-sensitivity likely explains 
the reported failure of MOAB-2 immunoreactivity to detect 
AD cases from pre-heated basal forebrain lysate following 
dot blot analysis by others [4] and thus highlights the need 
to carefully review both sample preparation and subsequent 
methods for Aβ quantification.
Even though our approach does not allow the detection 
of particular Aβ species, MOAB-2 does not cross-react 
with APP or other metabolites, and it binds a C-terminal 
epitope with stronger affinity to more toxic Aβ1–42 than 
to Aβ1–40, independent of aggregation state [77]). The 
increase in total soluble levels of Aβ with disease diagno-
sis is in line with ELISA-based measurements from corti-
cal tissue [19, 50]. Compared to measurements of insoluble 
Aβ [58] and plaque load [6, 59, 62], MOAB-2 reactivity 
provides much better correlation with cognitive decline 
(ranging from 0.46 up to 0.71) as well as improved cor-
relation with disease progression as established with the 
biochemical staging of Aβ [67]. Similarly, the immunore-
active levels of soluble Aβ correlated with all tau markers 
tested (see below). In comparison, strong associations were 
not observed for pyro-glu Aβ: Although selective for diag-
nosis, elevations were only apparent between low and high 
Braak stage cases. Furthermore, pyro-glu Aβ only weakly 
correlated with individual Braak stages and failed to cor-
relate with any measure of cognition. This is largely at odds 
with previous reports of disease specificity [52] and toxic-
ity [61], although in agreement with previous work where 
a correlation was established between levels of pyro-glu-
modified Aβ and tau phosphorylation [52].
Early co‑localisation of soluble tau and amyloid 
pathology
It is fairly well established that Aβ plaques precede the 
emergence of NFTs in the neocortex, while NFTs are 
formed earlier in limbic areas [74]. However, our find-
ings clearly indicate that initial emergence of tau pathol-
ogy coincides with increased soluble Aβ in Brodmann area 
21 as early as Braak stages 2–3. This pathology therefore 
precedes the emergence of mature NFTs, classically deter-
mined at Braak stage 4 in this brain region. Thus, our data 
suggest a closer overlap for soluble Aβ and tau species in 
the temporal lobe, contrasting with the spatial separation 
of the two toxic pathways based on the mature fibrillary 
forms of these proteins. Thus, at least in Brodmann area 21, 
the early co-localization of soluble tau and Aβ pathology 
implies a close spatiotemporal relationship between these 
two pathologies.
In summary, our findings are supportive of the coinci-
dent emergence of disease-relevant, soluble, pre-fibrillar 
forms of both Aβ and tau during the earliest stages of AD. 
Potentially toxic protein species identified here strongly 
correlate with Braak staging and cognitive decline. Causal 
and functional links between Aβ and tau pathways will 
remain a hotly debated topic, but here we provide evidence 
that both pre-fibrillar Aβ and tau appear as likely contribu-
tors to the pathogenesis of AD. Late-stage insoluble protein 
aggregates may have very little relevance to the pathogenic 
mechanisms of disease, and therefore targeting pre-fibrillar 
tau and/or Aβ species will be a more effective therapeutic 
strategy for AD.
Acknowledgments We would like to gratefully acknowledge all 
donors and their families for the tissue provided for this study. Human 
tissue samples were supplied by the Brains for Dementia Research 
programme, jointly funded by Alzheimer’s Research UK, the Alzhei-
mer’s Society and the Medical Research Council, and sourced from 
the MRC London Neurodegenerative Diseases Brain Bank, the Man-
chester Brain Bank, the South West Dementia Brain Bank (SWDBB), 
the Newcastle Brain Tissue Resource and the Oxford Brain Bank. 
The Newcastle Brain Tissue Resource and Oxford Brain Bank are 
also supported by the National Institute for Health Research (NIHR) 
Units. The South West Dementia Brain Bank (SWDBB) receives 
additional support from BRACE (Bristol Research into Alzheimer’s 
and Care of the Elderly). Alz-50, CP13, MC-1 and PHF-1 antibodies 
were gifted from Dr. Peter Davies and brain lystates from BACE1−/− 
mice were obtained from Prof Mike Ashford. The work presented 
here was funded by Alzheimer’s Research UK (Grant refs: ARUK-
PPG2014A-21 and ARUK-NSG2015-1 to BP and DK and NIH/NIA 
grants NIH/NINDS R01 NS082730 and R01 AG044372 to NK).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP 
(2010) BACE1 and BACE2 enzymatic activities in Alzheimer’s 
disease. J Neurochem 112:1045–1053
 2. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, 
Braak H et al (2008) Staging of neurofibrillary pathology in Alz-
heimer’s disease: a study of the BrainNet Europe Consortium. 
Brain Pathol 18:484–496
 3. Arai H, Lee VM, Messinger ML, Greenberg BD, Lowery DE, 
Trojanowski JQ (1991) Expression patterns of β-amyloid pre-
cursor protein (β-APP) in neural and nonneural human tissues 
from Alzheimer’s disease and control subjects. Ann Neurol 
30:686–693
Acta Neuropathol 
1 3
 4. Baker-Nigh A, Vahedi S, Davis EG, Weintraub S, Bigio EH, 
Klein WL et al (2015) Neuronal amyloid-β accumulation within 
cholinergic basal forebrain in ageing and Alzheimer’s disease. 
Brain 138:1722–1737
 5. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Jan-
son B et al (2005) Globular amyloid beta-peptide oligomer—a 
homogenous and stable neuropathological protein in Alzheimer’s 
disease. J Neurochem 95:834–847
 6. Berg L, McKeel DW Jr, Miller JP, Storandt M, Rubin EH, Morris 
JC et al (1998) Clinicopathologic studies in cognitively healthy 
aging and Alzheimer’s disease: relation of histologic markers to 
dementia severity, age, sex, and apolipoprotein E genotype. Arch 
Neurol 55:326–335
 7. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue 
M et al (2007) Accumulation of pathological tau species and 
memory loss in a conditional model of tauopathy. J Neurosci 
27:3650–3662
 8. Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, Ferrer I et al 
(2004) Upregulation of amyloid precursor protein isoforms con-
taining Kunitz protease inhibitor in dementia with Lewy bodies. 
Brain Res Mol Brain Res 131:131–135
 9. Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, 
Steiner B, Berling B et al (1992) The switch of tau protein to 
an Alzheimer-like state includes the phosphorylation of two ser-
ine-proline motifs upstream of the microtubule binding region. 
EMBO J 11:1593–1597
 10. Bitan G, Fradinger EA, Spring SM, Teplow DB (2005) Neuro-
toxic protein oligomers—what you see is not always what you 
get. Amyloid 12:88–95
 11. Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in 
Alzheimer disease pathogenesis. JAMA Neurol 71:505–508
 12. Boluda S, Toledo JB, Irwin DJ, Raible KM, Byrne MD, Lee EB 
et al (2014) A comparison of Aβ amyloid pathology staging sys-
tems and correlation with clinical diagnosis. Acta Neuropathol 
128:543–550
 13. Borzova VA, Markossian KA, Kara DA, Kurganov B (2015) 
Kinetic regime of dithiothreitol-induced aggregation of bovine 
serum albumin. Int J BiolMacromol 80:130–138
 14. Bowser R, Giambrone A, Davies P (1995) FAC1, a novel gene 
identified with the monoclonal antibody Alz50, is developmen-
tally regulated in human brain. Dev Neurosci 17:20–37
 15. Braak H, Braak E (1995) Staging of Alzheimer’s disease-related 
neurofibrillary changes. Neurobiol Aging 16:271–284
 16. Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, 
Christensen J et al (2016) Tau and Aβ imaging, CSF measures, 
and cognition in Alzheimer’s disease. Sci Transl Med 8:338ra66
 17. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR 
(2000) Tau protein isoforms, phosphorylation and role in neuro-
degenerative disorders. Brain Res Brain Res Rev 33:95–130
 18. Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, 
Bien-Ly N et al (2007) Accelerating amyloid-β fibrillization 
reduces oligomer levels and functional deficits in Alzheimer dis-
ease mouse models. J Biol Chem 282:23818–23828
 19. Collins-Praino LE, Francis YI, Griffith EY, Wiegman AF, Urbach 
J, Lawton A et al. (2014) Soluble amyloid beta levels are ele-
vated in the white matter of Alzheimer’s patients, independent 
of cortical plaque severity. Acta Neuropathol Commun 2:83. 
doi:10.1186/s40478-014-0083-0
 20. Crowther RA, Olesen OF, Smith MJ, Jakes R, Goedert M (1994) 
Assembly of Alzheimer-like filaments from full-length tau pro-
tein. FEBS Lett 337:135–138
 21. Cynis H, Scheel E, Saido TC, Schilling S, Demuth HU (2008) 
Amyloidogenic processing of amyloid precursor protein: 
evidence of a pivotal role of glutaminyl cyclase in genera-
tion of pyroglutamate-modified amyloid-beta. Biochemistry 
47:7405–7413
 22. Fa M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons 
MA et al (2016) Extracellular Tau oligomers produce an imme-
diate impairment of LTP and memory. Sci Rep 6:19393
 23. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S 
et al (2007) Brain protein preservation largely depends on the 
postmortem storage temperature: implications for study of pro-
teins in human neurologic diseases and management of brain 
banks: a BrainNet Europe Study. J Neuropathol Exp Neurol 
66:35–46
 24. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC (2002) 
β-Secretase protein and activity are increased in the neocortex in 
Alzheimer disease. Arch Neurol 59:1381–1389
 25. Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, 
Berry RW et al (2002) Tau conformational changes correspond 
to impairments of episodic memory in mild cognitive impair-
ment and Alzheimer’s disease. Exp Neurol 177:475–493
 26. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari 
E, Perl DP et al (2003) Tangle and neuron numbers, but not amy-
loid load, predicts cognitive status in Alzheimer’s disease. Neu-
rology 60:1495–1500
 27. Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal anti-
body AT8 recognises tau protein phosphorylated at both serine 
202 and threonine 205. Neurosci Lett 189:167–169
 28. Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, 
Berry RW, Binder LI (2006) Pseudophosphorylation of tau at 
serine 422 inhibits caspase cleavage: in vitro evidence and impli-
cations for tangle formation in vivo. J Neurochem 97:1005–1014
 29. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid 
cascade hypothesis. Science 256:184–185
 30. Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP 
(2007) Tau protein abnormalities associated with the progression 
of alzheimer disease type dementia. Neurobiol Aging 28:1–7
 31. Hatami A, 3rd Albay R, Monjazeb S, Milton S, Glabe C (2014) 
Monoclonal antibodies against Aβ42 fibrils distinguish multiple 
aggregation state polymorphisms in vitro and in Alzheimer dis-
ease brain. J Biol Chem 289:32131–32143
 32. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, 
Acton P et al (2006) Solution state characterization of amyloid 
β-derived diffusible ligands. Biochemistry 45:15157–15167
 33. Holden P, Horton WA (2009) Crude subcellular fractionation of 
cultured mammalian cell lines. BMC Res Notes 2:243
 34. Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin 
G (2002) Increased expression of the amyloid precursor beta-
secretase in Alzheimer’s disease. Ann Neurol 51:783–786
 35. Iqbal K, Gong CX, Liu F (2013) Hyperphosphorylation-induced 
tau oligomers. Front Neurol 4:112
 36. Jeganathan S, Hascher A, Chinnathambi S, Biernat J, Man-
delkow EM, Mandelkow E (2008) Proline-directed pseudo-phos-
phorylation at AT8 and PHF1 epitopes induces a compaction of 
the paperclip folding of Tau and generates a pathological (MC-1) 
conformation. J BiolChem 283:32066–32076
 37. Jicha GA, Bowser R, Kazam IG, Davies P (1997) Alz-50 and 
MC-1, a new monoclonal antibody raised to paired helical fila-
ments, recognize conformational epitopes on recombinant tau. J 
Neurosci Res 48:128–132
 38. Jimenez S, Navarro V, Moyano J, Sanchez-Mico M, Torres M, 
Davila JC et al (2014) Disruption of amyloid plaques integrity 
affects the soluble oligomers content from Alzheimer disease 
brains. PLoS One 9:e114041
 39. Jyoti A, Plano A, Riedel G, Platt B (2010) EEG, activity, and 
sleep architecture in a transgenic AbetaPPswe/PSEN1A246E 
Alzheimer’s disease mouse. J Alzheimers Dis 22:873–887
 40. Kanaan NM, Cox K, Alvarez VE, Stein TD, Poncil S, McKee AC 
(2016) Characterization of early pathological Tau conformations 
and phosphorylation in chronic traumatic encephalopathy. J Neu-
ropathol Exp Neurol 75:19–34
 Acta Neuropathol
1 3
 41. Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson 
KR, Song Y et al (2011) Pathogenic forms of tau inhibit kinesin-
dependent axonal transport through a mechanism involving acti-
vation of axonal phosphotransferases. J Neurosci 31:9858–9868
 42. King ME, Gamblin TC, Kuret J, Binder LI (2000) Differential 
assembly of human tau isoforms in the presence of arachidonic 
acid. J Neurochem 74:1749–1757
 43. Koss DJ, Robinson L, Drever BD, Plucinska K, Stoppelkamp S, 
Veselcic P et al (2016) Mutant Tau knock-in mice display fronto-
temporal dementia relevant behaviour and histopathology. Neu-
robiol Dis 91:105–123
 44. Koss DJ, Robinson L, Mietelska-Porowska A, Gasiorowska A, 
Sepcic K, Turk T et al (2015) Polymeric alkylpyridinium salts 
permit intracellular delivery of human Tau in rat hippocampal 
neurons: requirement of Tau phosphorylation for functional defi-
cits. Cell Mol Life Sci 72:4613–4632
 45. Kumar S, Ravi VK, Swaminathan R (2008) How do surfactants 
and DTT affect the size, dynamics, activity and growth of solu-
ble lysozyme aggregates? Biochem J 415:275–288
 46. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, 
Jackson GR, Kayed R (2010) Preparation and characterization of 
neurotoxic tau oligomers. Biochemistry 49:10039–10041
 47. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos 
AL, Jackson GR, Kayed R (2011) Tau oligomers impair memory 
and induce synaptic and mitochondrial dysfunction in wild-type 
mice. Mol Neurodegener 6:39. doi:10.1186/1750-1326-6-39
 48. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A 
et al (2006) A specific amyloid-β protein assembly in the brain 
impairs memory. Nature 440:352–357
 49. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, 
Bennett DA et al (2013) Brain amyloid-β oligomers in ageing 
and Alzheimer’s disease. Brain 136:1383–1398
 50. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al 
(1999) Soluble amyloid β peptide concentration as a predic-
tor of synaptic change in Alzheimer’s disease. Am J Pathol 
155:853–862
 51. Luna-Munoz J, Garcia-Sierra F, Falcon V, Menendez I, Chavez-
Macias L, Mena R (2005) Regional conformational change 
involving phosphorylation of tau protein at the Thr231, precedes 
the structural change detected by Alz-50 antibody in Alzheimer’s 
disease. J Alzheimers Dis 8:29–41
 52. Mandler M, Walker L, Santic R, Hanson P, Upadhaya AR, Col-
loby SJ et al (2014) Pyroglutamylated amyloid-β is associated 
with hyperphosphorylated tau and severity of Alzheimer’s dis-
ease. Acta Neuropathol 128:67–79
 53. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, 
Wekstein DR (2006) Neuropathologic substrate of mild cogni-
tive impairment. Arch Neurol 63:38–46
 54. Meakin PJ, Harper AJ, Hamilton DL, Gallagher J, McNeilly AD, 
Burgess LA et al (2012) Reduction in BACE1 decreases body 
weight, protects against diet-induced obesity and enhances insu-
lin sensitivity in mice. Biochem J 441:285–296
 55. Morris GP, Clark IA, Vissel B (2014) Inconsistencies and contro-
versies surrounding the amyloid hypothesis of Alzheimer’s dis-
ease. Acta Neuropathol Commun 2:135
 56. Morsch R, Simon W, Coleman PD (1999) Neurons may live for 
decades with neurofibrillary tangles. J Neuropathol Exp Neurol 
58:188–197
 57. Mufson EJ, Malek-Ahmadi M, Perez SE, Chen K (2016) Braak 
staging, plaque pathology, and APOE status in elderly persons 
without cognitive impairment. Neurobiol Aging 37:147–153
 58. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Green-
gard P et al (2000) Correlation between elevated levels of 
amyloid β-peptide in the brain and cognitive decline. JAMA 
283:1571–1577
 59. Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo 
MS et al (2007) Clinicopathologic correlations in a large Alzhei-
mer disease center autopsy cohort: neuritic plaques and neurofi-
brillary tangles “do count” when staging disease severity. J Neu-
ropathol Exp Neurol 66:1136–1146
 60. Nordstedt C, Gandy SE, Alafuzoff I, Caporaso GL, Iverfeldt 
K, Grebb JA et al (1991) Alzheimer beta/A4 amyloid precur-
sor protein in human brain: aging-associated increases in holo-
protein and in a proteolytic fragment. Proc Natl Acad Sci USA 
88:8910–8914
 61. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangs-
anut T et al (2012) Prion-like behaviour and tau-dependent cyto-
toxicity of pyroglutamylated amyloid-β. Nature 485:651–655
 62. Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis 
KL, Mohs RC et al (2001) Correlation between Abetax-40-, 
Abetax-42-, and Abetax-43-containing amyloid plaques and cog-
nitive decline. Arch Neurol 58:2025–2032
 63. Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana 
L et al (2011) Characterization of prefibrillar Tau oligomers 
in vitro and in Alzheimer disease. J Biol Chem 286:23063–23076
 64. Patterson KR, Ward SM, Combs B, Voss K, Kanaan NM, Morfini 
G et al (2011) Heat shock protein 70 prevents both tau aggrega-
tion and the inhibitory effects of preexisting tau aggregates on 
fast axonal transport. Biochemistry 50:10300–10310
 65. Plucinska K, Crouch B, Koss D, Robinson L, Siebrecht M, Rie-
del G et al (2014) Knock-in of human BACE1 cleaves murine 
APP and reiterates Alzheimer-like phenotypes. J Neurosci 
34:10710–10728
 66. Pujol-Pina R, Vilaprinyo-Pascual S, Mazzucato R, Arcella 
A, Vilaseca M, Orozco M et al (2015) SDS-PAGE analysis of 
Aβ oligomers is disserving research into Alzheimer s disease: 
appealing for ESI-IM-MS. Sci Rep 5:14809
 67. RijalUpadhaya A, Kosterin I, Kumar S, von Arnim CA, Yamagu-
chi H, Fandrich M et al (2014) Biochemical stages of amyloid-
beta peptide aggregation and accumulation in the human brain 
and their association with symptomatic and pathologically pre-
clinical Alzheimer’s disease. Brain 137:887–903
 68. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson 
M et al (2005) Tau suppression in a neurodegenerative mouse 
model improves memory function. Science 309:476–481
 69. Sasahara K, Yagi H, Naiki H, Goto Y (2007) Heat-induced con-
version of β(2)-microglobulin and hen egg-white lysozyme into 
amyloid fibrils. J MolBiol 372:981–991
 70. Schonheit B, Zarski R, Ohm TG (2004) Spatial and temporal 
relationships between plaques and tangles in Alzheimer-pathol-
ogy. Neurobiol Aging 25:697–711
 71. Serrano-Pozo A, Qian J, Muzikansky A, Monsell SE, Montine 
TJ, Frosch MP et al (2016) Thal amyloid stages do not signifi-
cantly impact the correlation between neuropathological change 
and cognition in the Alzheimer disease continuum. J Neuro-
pathol Exp Neurol 75:516–526
 72. Stockley JH, Ravid R, O’Neill C (2006) Altered β-secretase 
enzyme kinetics and levels of both BACE1 and BACE2 in the 
Alzheimer’s disease brain. FEBS Lett 580:6550–6560
 73. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of 
Aβ-deposition in the human brain and its relevance for the devel-
opment of AD. Neurology 58:1791–1800
 74. Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del 
Tredici K et al (2000) Sequence of Aβ-protein deposition in 
the human medial temporal lobe. J Neuropathol Exp Neurol 
59:733–748
 75. Tharp WG, Lee YH, Greene SM, Vincellete E, Beach TG, Prat-
ley RE (2012) Measurement of altered AβPP isoform expression 
in frontal cortex of patients with Alzheimer’s disease by absolute 
quantification real-time PCR. J Alzheimers Dis 29:449–457
Acta Neuropathol 
1 3
 76. Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-
Lage P, Bocchio-Chiavetto L et al (2015) Alzheimer’s disease 
cerebrospinal fluid biomarker in cognitively normal subjects. 
Brain 138:2701–2715
 77. Youmans KL, Tai LM, Kanekiyo T, Stine WB Jr, Michon SC, 
Nwabuisi-Heath E et al. (2012) Intraneuronal Aβ detection in 
5xFAD mice by a new Aβ-specific antibody. Mol Neurodegener 
7:8. doi:10.1186/1750-1326-7-8
 78. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, 
Salvado O et al (2013) Amyloid beta deposition, neurodegen-
eration, and cognitive decline in sporadic Alzheimer’s disease: a 
prospective cohort study. Lancet Neurol 12:357–367
 79. Ward SM, Himmelstein DS, Lancia JK, Fu Y, Patterson KR, 
Binder LI (2013) TOC1: characterization of a selective oligo-
meric tau antibody. J Alzheimers Dis 37:593–602
 80. Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, Johans-
sen T et al (2013) Oligomers, fact or artefact? SDS-PAGE 
induces dimerization of β-amyloid in human brain samples. Acta 
Neuropathol 125:549–564
 81. Weaver CL, Espinoza M, Kress Y, Davies P (2000) Conforma-
tional change as one of the earliest alterations of tau in Alzhei-
mer’s disease. Neurobiol Aging 21:719–727
 82. Webster MT, Francis PT, Procter AW, Stratmann GC, Doshi R, 
Mann DM et al (1994) Postmortem brains reveal similar but 
not identical amyloid precursor protein-like immunoreactiv-
ity in Alzheimer compared with other dementias. Brain Res 
644:347–351
 83. Xu H, Rosler TW, Carlsson T, de Andrade A, Bruch J, Holler-
hage M et al (2014) Memory deficits correlate with tau and spine 
pathology in P301S MAPT transgenic mice. Neuropathol Appl 
Neurobiol 40:833–843
 84. Zhou XW, Li X, Bjorkdahl C, Sjogren MJ, Alafuzoff I, Soininen 
H et al (2006) Assessments of the accumulation severities of 
amyloid β-protein and hyperphosphorylated tau in the medial 
temporal cortex of control and Alzheimer’s brains. Neurobiol 
Dis 22:657–668
